INHIBITORY EFFECT OF QUERCETIN ON OVCA-433 CELLS AND PRESENCE OF TYPE-II ESTROGEN BINDING-SITES IN PRIMARY OVARIAN-TUMORS AND CULTURED-CELLS

被引:133
作者
SCAMBIA, G
RANELLETTI, FO
PANICI, PB
PIANTELLI, M
BONANNO, G
DEVINCENZO, R
FERRANDINA, G
RUMI, C
LAROCCA, LM
MANCUSO, S
机构
[1] UNIV CATTOLICA SACRO CUORE, DEPT GYNAECOL, LARGO A GEMELLI 8, I-00168 ROME, ITALY
[2] UNIV CATTOLICA SACRO CUORE, DEPT HISTOL, I-00168 ROME, ITALY
[3] UNIV CATTOLICA SACRO CUORE, DEPT PATHOL, I-00168 ROME, ITALY
[4] UNIV CATTOLICA SACRO CUORE, DEPT HAEMATOL, I-00168 ROME, ITALY
关键词
D O I
10.1038/bjc.1990.414
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the effect of the flavonoid quercetin (Q) on the proliferation of the ovarian cancer cell line OVCA 433. Growth experiments demonstrated that Q exerted a reversible dose-dependent inhibition of cell proliferation in the range of concentrations between 10 nM and 10 pM. Two other flavonoids tested, rutin and hesperidin, were ineffective in inhibiting cell growth. Cell cycle analysis showed that the growth inhibitory effect of Q was due to a blocking effect in the GO/G1 phase. Using a whole cell assay with (6, 7-3H) oestradiol (3H-E2) as tracer we demonstrated that OVCA 433 cells contain type II oestrogen binding sites (type II EBS). Competition analysis showed that Q competed for3H-E2 binding to type II EBS while both rutin and hesperidin did not. Appreciable amounts of type II EBS were also detected in seven primary ovarian tumours. Our results suggest that Q may regulate ovarian cancer cell growth through a mechanism involving a binding interaction with type II EBS. This mechanism could also be active in vivo since primary ovarian tumours contain type II EBS. © Macmillan Press Ltd., 1990.
引用
收藏
页码:942 / 946
页数:5
相关论文
共 27 条
[1]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[2]   HIGH AEROBIC GLYCOLYSIS OF RAT HEPATOMA-CELLS IN CULTURE - ROLE OF MITOCHONDRIAL HEXOKINASE - (L-LACTIC ACID-D-GLUCOSE-D-GALACTOSE-LIVER-NEOPLASIA) [J].
BUSTAMANTE, E ;
PEDERSEN, PL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (09) :3735-3739
[3]   EFFECT OF ELLAGIC ACID AND HYDROXYLATED FLAVONOIDS ON THE TUMORIGENICITY OF BENZO[A]PYRENE AND (+/-)-7-BETA,8-ALPHA-DIHYDROXY-9-ALPHA,10-ALPHA-EPOXY-7,8,9,10-TETRAHYDROBENZO[A]PYRENE ON MOUSE SKIN AND IN THE NEWBORN MOUSE [J].
CHANG, RL ;
HUANG, MT ;
WOOD, AW ;
WONG, CQ ;
NEWMARK, HL ;
YAGI, H ;
SAYER, JM ;
JERINA, DM ;
CONNEY, AH .
CARCINOGENESIS, 1985, 6 (08) :1127-1133
[4]  
CLARK JH, 1978, J BIOL CHEM, V253, P7630
[5]  
Gabor M., 1988, PLANT FLAVONOIDS BIO, P1
[6]   BIOFLAVONOID REGULATION OF ATPASE AND HEXOKINASE ACTIVITY IN EHRLICH ASCITES CELL MITOCHONDRIA [J].
GRAZIANI, Y .
BIOCHIMICA ET BIOPHYSICA ACTA, 1977, 460 (02) :364-373
[7]   THE EFFECT OF QUERCETIN ON THE PHOSPHORYLATION ACTIVITY OF THE ROUS-SARCOMA VIRUS TRANSFORMING GENE-PRODUCT INVITRO AND INVIVO [J].
GRAZIANI, Y ;
ERIKSON, E ;
ERIKSON, RL .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1983, 135 (03) :583-589
[8]   DISPOSITION OF QUERCETIN IN MAN AFTER SINGLE ORAL AND INTRAVENOUS DOSES [J].
GUGLER, R ;
LESCHIK, M ;
DENGLER, HJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1975, 9 (2-3) :229-234
[9]  
HOFFMAN J, 1988, P AM ASSOC CANC RES, V29, P481
[10]  
HOFFMANN J, 1989, BRIT J CANCER, V59, P347